244 related articles for article (PubMed ID: 30027791)
41. Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients: a German-Austrian, single-arm, open-label, prospective, noninterventional, observational study.
Biggar P; Kovarik J; Klauser-Braun R; Graf H; Müller HW; Veres A; Seidinger S; Ketteler M
Nephron Clin Pract; 2014; 126(1):39-50. PubMed ID: 24458019
[TBL] [Abstract][Full Text] [Related]
42. [Effect of cinacalcet combined with low-dose calcitriol on clinical outcome and bone metabolism in patients with severe secondary hyperparathyroidism].
Yuan F; Chen X; Wang C; Zhou A; Liu H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 42(10):1169-1173. PubMed ID: 29093248
[TBL] [Abstract][Full Text] [Related]
43. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
[TBL] [Abstract][Full Text] [Related]
44. Cinacalcet may reduce arterial stiffness in patients with chronic renal disease and secondary hyperparathyroidism - results of a small-scale, prospective, observational study.
Bonet J; Bayés B; Fernández-Crespo P; Casals M; López-Ayerbe J; Romero R
Clin Nephrol; 2011 Mar; 75(3):181-7. PubMed ID: 21329627
[TBL] [Abstract][Full Text] [Related]
45. Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism.
Yu L; Tomlinson JE; Alexander ST; Hensley K; Han CY; Dwyer D; Stolina M; Dean C; Goodman WG; Richards WG; Li X
Calcif Tissue Int; 2017 Dec; 101(6):641-653. PubMed ID: 29038882
[TBL] [Abstract][Full Text] [Related]
46. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism.
Fukagawa M; Shimazaki R; Akizawa T;
Kidney Int; 2018 Oct; 94(4):818-825. PubMed ID: 30049473
[TBL] [Abstract][Full Text] [Related]
47. Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.
Chen P; Narayanan A; Wu B; Gisleskog PO; Gibbs JP; Chow AT; Melhem M
Clin Pharmacokinet; 2018 Jan; 57(1):71-85. PubMed ID: 28508378
[TBL] [Abstract][Full Text] [Related]
48. Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients.
Zheng CM; Wu CC; Hung CF; Liao MT; Shyu JF; Hsu YH; Lu CL; Wang YH; Zheng JQ; Chang TJ; Lin YF; Lu KC
Nutrients; 2018 Feb; 10(2):. PubMed ID: 29439405
[TBL] [Abstract][Full Text] [Related]
49. [The Discovery, Research and Development of Etelcalcetide Hydrochloride, the World 1st Intravenous Calcimimetics.].
Inoue A; Harada K
Clin Calcium; 2017; 27(4):537-545. PubMed ID: 28336830
[TBL] [Abstract][Full Text] [Related]
50. Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis.
Ye J; Deng G; Gao F
Drug Des Devel Ther; 2018; 12():901-909. PubMed ID: 29719376
[TBL] [Abstract][Full Text] [Related]
51. Gallstones were associated with the gastrointestinal adverse events of cinacalcet in hemodialysis patients with secondary hyperparathyroidism.
Otsuka K; Ohno Y; Oshima J
Ren Fail; 2018 Nov; 40(1):38-42. PubMed ID: 29301445
[TBL] [Abstract][Full Text] [Related]
52. Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients.
Cooper K; Quarles D; Kubo Y; Tomlin H; Goodman W
Nephron Clin Pract; 2012; 121(3-4):c124-30. PubMed ID: 23208191
[TBL] [Abstract][Full Text] [Related]
53. Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis.
Pérez-Ricart A; Galicia-Basart M; Alcalde-Rodrigo M; Segarra-Medrano A; Suñé-Negre JM; Montoro-Ronsano JB
PLoS One; 2016; 11(9):e0161527. PubMed ID: 27588942
[TBL] [Abstract][Full Text] [Related]
54. Development of evocalcet for unmet needs among calcimimetic agents.
Hamano N; Endo Y; Kawata T; Fukagawa M
Expert Rev Endocrinol Metab; 2020 Sep; 15(5):299-310. PubMed ID: 32552012
[TBL] [Abstract][Full Text] [Related]
55. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
[TBL] [Abstract][Full Text] [Related]
56. Trajectories of CKD-MBD biochemical parameters over a 2-year period following diagnosis of secondary hyperparathyroidism: a pharmacoepidemiological study.
Filipozzi P; Ayav C; Ngueyon Sime W; Laurain E; Kessler M; Brunaud L; Frimat L
BMJ Open; 2017 Mar; 7(3):e011482. PubMed ID: 28348181
[TBL] [Abstract][Full Text] [Related]
57. A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride.
Nakamura H; Tokumoto M; Anayama M; Kurihara S; Makino Y; Tamura K; Nagasawa M
CEN Case Rep; 2022 May; 11(2):254-258. PubMed ID: 34787825
[TBL] [Abstract][Full Text] [Related]
58. Use of cinacalcet for the management of hyperparathyroidism in patients with different degrees of renal failure.
Orellana JM; Esteban RJ; Castilla YA; Fernández-Castillo R; Nozal-Fernández G; Esteban MA; García-Valverde M; Bravo J
Nefrologia; 2016; 36(2):121-5. PubMed ID: 26906451
[TBL] [Abstract][Full Text] [Related]
59. Tolerance and efficacy of a low dose of the calcimimetic agent cinacalcet in controlling moderate to severe secondary hyperparathyroidism in hemodialysis patients.
Bashir SO; Omer HA; Aamer MA; Somialy R; Morsy MD
Saudi J Kidney Dis Transpl; 2015 Nov; 26(6):1135-41. PubMed ID: 26586050
[TBL] [Abstract][Full Text] [Related]
60. Etelcalcetide versus placebo for secondary hyperparathyroidism in patients receiving hemodialysis: A meta-analysis of randomized controlled trials.
Zhu Y; Ou J; Liu X; Xie Z
Clin Nephrol; 2020 Oct; 94(4):173-180. PubMed ID: 32729818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
